Prøve GULL - Gratis

Digital Innovations in Diabetes Care

BioSpectrum Asia

|

BioSpectrum Asia Nov 2024

Diabetes affects 537 million people globally and is a major contributor to the non-communicable disease NCD) epidemic. Technological tools such as continuous glucose monitors CGMs) and mobile apps are redefining diabetes management. On this World Diabetes Day November 14, 2024), we explore how digital health is transforming diabetes care and the challenges associated with its integration into healthcare systems.

- Ayesha Siddiqui

Digital Innovations in Diabetes Care

Diabetes affects 1 in 11 adults, or about 90 million people, in South-East Asia, with this number projected to rise to 113 million by 2030 and 151 million by 2045. Alarmingly, over half of these individuals remain undiagnosed. In 2021, diabetes caused 747,000 deaths in the region, and the economic burden of managing the disease reached $10 billion, as per the 2021 IDF Diabetes Atlas.

Technological advancements have proven to be a boon for diabetes care, offering various tools to help manage the condition effectively. One of the critical aspects of diabetes management is maintaining optimal glucose levels at all times. Digital health tools, such as continuous glucose monitors (CGMs), connected insulin pens, portable A1C monitors, and mobile apps, are transforming the way patients manage their condition outside of hospitals. Mobile apps enable healthcare providers to create personalised treatment plans based on real-time data.

Another innovation is the automated insulin delivery (AID) system, which integrates CGMs and insulin pumps to adjust insulin delivery continuously based on glucose data. Portable A1C monitors allow patients to measure their A1C levels at home, an essential marker for long-term diabetes management.

“Previously, patients had limited information about their condition, which led to anxiety and a lack of motivation for managing it. Now, with tools like CGMs, personal A1C monitors, and mobile apps, patients can check their levels anytime, anywhere, and easily access professional support through mobile platforms. This not only reduces uncertainty but also empowers them to receive more frequent feedback, stay motivated, and proactively manage their health. Ultimately, this leads to better health outcomes by making diabetes management more accessible and proactive,” said Yeaseul Park, Co-Founder and Co-President Orange Biomed, USA.

FLERE HISTORIER FRA BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

India signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

New Zealand to lead new gene therapy trial for muscular dystrophy

The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Scientists in Australia grow living skin in world-first

Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare

HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund

Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan

Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium

Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Korea makes smart patch that can run tests using sweat instead of blood

A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka

The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines

China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.

time to read

1 min

BioSpectrum Asia Oct 2025

Listen

Translate

Share

-
+

Change font size